Nasal powder: A stable, rapid-onset strategy for systemic therapy

Nasal powder formulations represent a significant stride in drug delivery innovation, offering the potential for simplified, preservative-free compositions. Increased chemical stability and enhanced capacity for higher drug loads are additional benefits offered by formulating as a dry powder. Application of established production technologies, such as spray drying, allows for the design and manufacture of readily dispersible, shelf-stable powders in a scalable process.

This article discusses a wide range of topics on these innovative formulations including potential indications and applications such as neurological disorders, vaccines, interactions with mucosal barriers and emergency anaphylaxis treatment; formulation and characterization approaches, particularly formulation considerations and excipient selection; manufacture of nasal powder utilizing spray drying and new technologies such as thin-film freeze drying; in vitro characterization; and trends and challenges entering and within the market, commercial examples and global regulatory trends.